Financhill
Sell
11

MLTX Quote, Financials, Valuation and Earnings

Last price:
$38.45
Seasonality move :
-2.28%
Day range:
$37.84 - $39.20
52-week range:
$36.52 - $58.26
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.48x
Volume:
300.2K
Avg. volume:
324.5K
1-year change:
-11.67%
Market cap:
$2.4B
Revenue:
--
EPS (TTM):
-$1.89

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
MLTX
MoonLake Immunotherapeutics
-- -$0.59 -- -247.27% $78.67
ACIU
AC Immune SA
$820.9K -$0.21 -95.08% -273.39% $10.08
ADXN
Addex Therapeutics
$177.2K -- 2.35% -- $30.00
CRSP
CRISPR Therapeutics AG
$7.3M -$1.19 -96.36% -11.56% $83.60
MOLN
Molecular Partners AG
-- -$0.45 -100% -8.38% $10.78
NLSP
NLS Pharmaceutics
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
MLTX
MoonLake Immunotherapeutics
$38.67 $78.67 $2.4B -- $0.00 0% --
ACIU
AC Immune SA
$2.29 $10.08 $226.6M -- $0.00 0% --
ADXN
Addex Therapeutics
$7.54 $30.00 $8.1M -- $0.00 0% 13.93x
CRSP
CRISPR Therapeutics AG
$42.12 $83.60 $3.6B -- $0.00 0% --
MOLN
Molecular Partners AG
$4.33 $10.78 $159.7M -- $0.00 0% 21.67x
NLSP
NLS Pharmaceutics
$1.58 -- $6M -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
MLTX
MoonLake Immunotherapeutics
-- 2.430 -- --
ACIU
AC Immune SA
-- 5.657 -- 1.66x
ADXN
Addex Therapeutics
-- 3.522 -- 4.36x
CRSP
CRISPR Therapeutics AG
-- 2.038 -- 21.97x
MOLN
Molecular Partners AG
-- 3.153 -- 14.08x
NLSP
NLS Pharmaceutics
-- 3.791 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
MLTX
MoonLake Immunotherapeutics
-- -$49.6M -- -- -- -$48.6M
ACIU
AC Immune SA
-- -$21.2M -37.26% -37.26% -1386.46% $5.4M
ADXN
Addex Therapeutics
-- -$719.5K 91.08% 91.08% -2836.3% -$713.3K
CRSP
CRISPR Therapeutics AG
$35M -$64.6M -18.65% -18.65% -184.54% -$50.3M
MOLN
Molecular Partners AG
-- -$16.8M -37.36% -37.36% -2407.93% -$14.2M
NLSP
NLS Pharmaceutics
-- -- -- -- -- --

MoonLake Immunotherapeutics vs. Competitors

  • Which has Higher Returns MLTX or ACIU?

    AC Immune SA has a net margin of -- compared to MoonLake Immunotherapeutics's net margin of -1389.36%. MoonLake Immunotherapeutics's return on equity of -- beat AC Immune SA's return on equity of -37.26%.

    Company Gross Margin Earnings Per Share Invested Capital
    MLTX
    MoonLake Immunotherapeutics
    -- -$0.72 --
    ACIU
    AC Immune SA
    -- -$0.18 $124.3M
  • What do Analysts Say About MLTX or ACIU?

    MoonLake Immunotherapeutics has a consensus price target of $78.67, signalling upside risk potential of 103.43%. On the other hand AC Immune SA has an analysts' consensus of $10.08 which suggests that it could grow by 340.11%. Given that AC Immune SA has higher upside potential than MoonLake Immunotherapeutics, analysts believe AC Immune SA is more attractive than MoonLake Immunotherapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    MLTX
    MoonLake Immunotherapeutics
    11 1 0
    ACIU
    AC Immune SA
    3 0 0
  • Is MLTX or ACIU More Risky?

    MoonLake Immunotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AC Immune SA has a beta of 1.226, suggesting its more volatile than the S&P 500 by 22.632%.

  • Which is a Better Dividend Stock MLTX or ACIU?

    MoonLake Immunotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MoonLake Immunotherapeutics pays -- of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MLTX or ACIU?

    MoonLake Immunotherapeutics quarterly revenues are --, which are smaller than AC Immune SA quarterly revenues of $1.3M. MoonLake Immunotherapeutics's net income of -$45.6M is lower than AC Immune SA's net income of -$18M. Notably, MoonLake Immunotherapeutics's price-to-earnings ratio is -- while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MoonLake Immunotherapeutics is -- versus -- for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MLTX
    MoonLake Immunotherapeutics
    -- -- -- -$45.6M
    ACIU
    AC Immune SA
    -- -- $1.3M -$18M
  • Which has Higher Returns MLTX or ADXN?

    Addex Therapeutics has a net margin of -- compared to MoonLake Immunotherapeutics's net margin of -2841.85%. MoonLake Immunotherapeutics's return on equity of -- beat Addex Therapeutics's return on equity of 91.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    MLTX
    MoonLake Immunotherapeutics
    -- -$0.72 --
    ADXN
    Addex Therapeutics
    -- -$2.78 $13.1M
  • What do Analysts Say About MLTX or ADXN?

    MoonLake Immunotherapeutics has a consensus price target of $78.67, signalling upside risk potential of 103.43%. On the other hand Addex Therapeutics has an analysts' consensus of $30.00 which suggests that it could grow by 297.88%. Given that Addex Therapeutics has higher upside potential than MoonLake Immunotherapeutics, analysts believe Addex Therapeutics is more attractive than MoonLake Immunotherapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    MLTX
    MoonLake Immunotherapeutics
    11 1 0
    ADXN
    Addex Therapeutics
    0 0 0
  • Is MLTX or ADXN More Risky?

    MoonLake Immunotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Addex Therapeutics has a beta of 1.757, suggesting its more volatile than the S&P 500 by 75.723%.

  • Which is a Better Dividend Stock MLTX or ADXN?

    MoonLake Immunotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Addex Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MoonLake Immunotherapeutics pays -- of its earnings as a dividend. Addex Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MLTX or ADXN?

    MoonLake Immunotherapeutics quarterly revenues are --, which are smaller than Addex Therapeutics quarterly revenues of $62.3K. MoonLake Immunotherapeutics's net income of -$45.6M is lower than Addex Therapeutics's net income of -$1.8M. Notably, MoonLake Immunotherapeutics's price-to-earnings ratio is -- while Addex Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MoonLake Immunotherapeutics is -- versus 13.93x for Addex Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MLTX
    MoonLake Immunotherapeutics
    -- -- -- -$45.6M
    ADXN
    Addex Therapeutics
    13.93x -- $62.3K -$1.8M
  • Which has Higher Returns MLTX or CRSP?

    CRISPR Therapeutics AG has a net margin of -- compared to MoonLake Immunotherapeutics's net margin of -106.6%. MoonLake Immunotherapeutics's return on equity of -- beat CRISPR Therapeutics AG's return on equity of -18.65%.

    Company Gross Margin Earnings Per Share Invested Capital
    MLTX
    MoonLake Immunotherapeutics
    -- -$0.72 --
    CRSP
    CRISPR Therapeutics AG
    -- -$0.44 $1.9B
  • What do Analysts Say About MLTX or CRSP?

    MoonLake Immunotherapeutics has a consensus price target of $78.67, signalling upside risk potential of 103.43%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $83.60 which suggests that it could grow by 98.48%. Given that MoonLake Immunotherapeutics has higher upside potential than CRISPR Therapeutics AG, analysts believe MoonLake Immunotherapeutics is more attractive than CRISPR Therapeutics AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    MLTX
    MoonLake Immunotherapeutics
    11 1 0
    CRSP
    CRISPR Therapeutics AG
    12 11 1
  • Is MLTX or CRSP More Risky?

    MoonLake Immunotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.767, suggesting its more volatile than the S&P 500 by 76.677%.

  • Which is a Better Dividend Stock MLTX or CRSP?

    MoonLake Immunotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MoonLake Immunotherapeutics pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MLTX or CRSP?

    MoonLake Immunotherapeutics quarterly revenues are --, which are smaller than CRISPR Therapeutics AG quarterly revenues of $35M. MoonLake Immunotherapeutics's net income of -$45.6M is lower than CRISPR Therapeutics AG's net income of -$37.3M. Notably, MoonLake Immunotherapeutics's price-to-earnings ratio is -- while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MoonLake Immunotherapeutics is -- versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MLTX
    MoonLake Immunotherapeutics
    -- -- -- -$45.6M
    CRSP
    CRISPR Therapeutics AG
    -- -- $35M -$37.3M
  • Which has Higher Returns MLTX or MOLN?

    Molecular Partners AG has a net margin of -- compared to MoonLake Immunotherapeutics's net margin of -2408.81%. MoonLake Immunotherapeutics's return on equity of -- beat Molecular Partners AG's return on equity of -37.36%.

    Company Gross Margin Earnings Per Share Invested Capital
    MLTX
    MoonLake Immunotherapeutics
    -- -$0.72 --
    MOLN
    Molecular Partners AG
    -- -$0.34 $165M
  • What do Analysts Say About MLTX or MOLN?

    MoonLake Immunotherapeutics has a consensus price target of $78.67, signalling upside risk potential of 103.43%. On the other hand Molecular Partners AG has an analysts' consensus of $10.78 which suggests that it could grow by 148.97%. Given that Molecular Partners AG has higher upside potential than MoonLake Immunotherapeutics, analysts believe Molecular Partners AG is more attractive than MoonLake Immunotherapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    MLTX
    MoonLake Immunotherapeutics
    11 1 0
    MOLN
    Molecular Partners AG
    3 1 0
  • Is MLTX or MOLN More Risky?

    MoonLake Immunotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Molecular Partners AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock MLTX or MOLN?

    MoonLake Immunotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Molecular Partners AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MoonLake Immunotherapeutics pays -- of its earnings as a dividend. Molecular Partners AG pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MLTX or MOLN?

    MoonLake Immunotherapeutics quarterly revenues are --, which are smaller than Molecular Partners AG quarterly revenues of $787.5K. MoonLake Immunotherapeutics's net income of -$45.6M is lower than Molecular Partners AG's net income of -$12.8M. Notably, MoonLake Immunotherapeutics's price-to-earnings ratio is -- while Molecular Partners AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MoonLake Immunotherapeutics is -- versus 21.67x for Molecular Partners AG. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MLTX
    MoonLake Immunotherapeutics
    -- -- -- -$45.6M
    MOLN
    Molecular Partners AG
    21.67x -- $787.5K -$12.8M
  • Which has Higher Returns MLTX or NLSP?

    NLS Pharmaceutics has a net margin of -- compared to MoonLake Immunotherapeutics's net margin of --. MoonLake Immunotherapeutics's return on equity of -- beat NLS Pharmaceutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MLTX
    MoonLake Immunotherapeutics
    -- -$0.72 --
    NLSP
    NLS Pharmaceutics
    -- -- --
  • What do Analysts Say About MLTX or NLSP?

    MoonLake Immunotherapeutics has a consensus price target of $78.67, signalling upside risk potential of 103.43%. On the other hand NLS Pharmaceutics has an analysts' consensus of -- which suggests that it could grow by 15089.87%. Given that NLS Pharmaceutics has higher upside potential than MoonLake Immunotherapeutics, analysts believe NLS Pharmaceutics is more attractive than MoonLake Immunotherapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    MLTX
    MoonLake Immunotherapeutics
    11 1 0
    NLSP
    NLS Pharmaceutics
    0 0 0
  • Is MLTX or NLSP More Risky?

    MoonLake Immunotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NLS Pharmaceutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock MLTX or NLSP?

    MoonLake Immunotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NLS Pharmaceutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MoonLake Immunotherapeutics pays -- of its earnings as a dividend. NLS Pharmaceutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MLTX or NLSP?

    MoonLake Immunotherapeutics quarterly revenues are --, which are smaller than NLS Pharmaceutics quarterly revenues of --. MoonLake Immunotherapeutics's net income of -$45.6M is higher than NLS Pharmaceutics's net income of --. Notably, MoonLake Immunotherapeutics's price-to-earnings ratio is -- while NLS Pharmaceutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MoonLake Immunotherapeutics is -- versus -- for NLS Pharmaceutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MLTX
    MoonLake Immunotherapeutics
    -- -- -- -$45.6M
    NLSP
    NLS Pharmaceutics
    -- -- -- --

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Qualcomm Stock: 5G Leader at a Bargain Price?
Qualcomm Stock: 5G Leader at a Bargain Price?

Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…

What Is Buffett Buying and Selling Now?
What Is Buffett Buying and Selling Now?

In Q4 of last year, Warren Buffett made a few…

3 Safest Stocks to Buy Now
3 Safest Stocks to Buy Now

With the S&P 500 now in correction and stocks selling…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
59
GRRR alert for Mar 15

Gorilla Technology Group [GRRR] is up 29.72% over the past day.

Sell
49
SMTC alert for Mar 15

Semtech [SMTC] is up 21.28% over the past day.

Buy
62
PLPC alert for Mar 15

Preformed Line Products [PLPC] is up 17.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock